Finerenone Drug Shows Promise for Broader Kidney Disease Treatment
Recent international studies have revealed that the kidney disease drug finerenone may benefit a wider range of patients than previously thought. Traditionally used to treat chronic kidney disease (CKD) associated with type 2 diabetes, finerenone has shown potential in helping patients with non-diabetic CKD and certain glomerular diseases. The findings, presented at the European Renal Association Congress and published in leading medical journals, indicate that finerenone can slow kidney function decline, reduce cardiovascular risks, and improve survival rates. The studies, including the FIND-CKD trial, demonstrated that finerenone reduced the risk of kidney failure, CKD progression, heart failure, and cardiovascular death by significant margins. 
